William Newman
Manchester University NHS Foundation Trust, The University of Manchester, University of Manchester
0000-0002-6382-4678
About
I am a clinician scientist having trained as a doctor in Manchester and then undertaken clinical research training in Manchester and Toronto. My main research has been on pharmacogenomics - how we can use genomic information to prevent side effects and and improve outcomes from medication. This has mainly focused on implementation into routine care by leading the world's first point of care genetic test in neonates to prevent hearing loss due to antibiotics and implementation in primary care for commonly prescribed drugs.
My research has led to the identification of several genes that result in rare inherited conditions resulting in accurate diagnosis, important information for affected families and now leading to new treatments.
I was the President of the European Society of Human Genetics 2024-25; am the Lead of the NHSE Network of Excellence in Pharmacogenomics and Medicines Optimisation and co-lead a theme on Rare Conditions in the NIHR Biomedical Research Centre:Manchester.
Employment
-
Manchester University NHS Foundation Trust Consultant2004 - Present
-
The University of Manchester
Education
-
University of Manchester MD PhD2004 - Present
-
The University of Manchester
Projects & Funding
Projects & funding information is unavailable.
Publications (415)
- Professional bodies: how best to promote and support individuals working in human genetics and genomics Save
- Letter to the Editor re: “Myh11 haploinsufficiency recapitulates megacystis and voiding dysfunction in a mouse model of MMIHS” Save
- Implementing pharmacogenetic-guided prescribing in general practice: a qualitative process evaluation Save
- Cardiovascular prescriber attitudes to pharmacogenomics: a survey by the ESC working group on cardiovascular pharmacotherapy Save
- Development and validation of an open data model for pharmacogenetics to enable semantic interoperability in clinical practice Save
- From science to service–overcoming clinical implementation barriers to population genomic screening Save
- Expanding the genotypic spectrum of combined oxidative phosphorylation deficiency 54 Save
- Self‐Reported Pharmacogenetic Medication Use in the Our Future Health Cohort Save
- Professional Bodies: How Best to Promote and Support Individuals Working in Human Genetics and Genomics Save
- Threshold-Based Overlap of Breast Cancer High-Risk Classification Using Family History, Polygenic Risk Scores, and Traditional Risk Models in 180,398 Women Save